Stellar Biotechnologies and Amaran Biotechnology are happy
to announce that their continuing alliance has proved successful in their
primary objective to meet GMP-grade specifications of Stellar KLH for OBI-822
immunotherapy. KLH (Keyhole Limpet Hemocyanin) is a protein that stimulates the
immune system while OBI-822 is the immunotherapy that uses this protein to
combat immune disorders, cancer, and inflammatory responses.
The two companies collaborated in 2013 to manufacture
OBI-822 so that it uses the Stellar KLH protein. Next, the companies hope to
create large scale optimization processes to commercial manufacturing levels
for widespread use. Amaran even commissioned a new biological production and
research center in Taiwan’s Hsinchu Biomedical Science Park in Hsinchu County,
Taiwan in preparation for immunotherapy expansion.
Stellar Biotechnologies is a world leader in KLH production
while boasting a manufacturing facility that is the first of its kind. Amaran
Biotechnology is a biopharmaceutical manufacturer that designs, develops, and
produces pharmaceuticals in Taiwan.
Catherine Brisson, Chief Operating Office for Stellar
Biotechnologies Inc., stated that,”Stellar’s collaboration with Amaran is an
exciting clinical project. She continued that, “Through close cooperation with
the Amaran team, we achieved each primary objective on-time and to the
particular specifications required. We look forward to the scale-up stage with
Amaran and to providing our partners with GMP Stellar KLH™ for their immunotherapy
programs.”
Similarly, Tessie Che, General Manager and Chair of Amaran’s
Board of Directors, stated, “We are very pleased with the success of our
alliance with Stellar Biotechnologies, and the progress made towards commercial
scale production of KLH for OBI-822.All of the programs that support OBI-822
and that will move this important immunotherapy closer to market launch are on
track.”
Thanks to their continued collaboration, Stellar and Amaran
have met the guidelines and specifications for the OBI-822 production alongside
with the development and formulation of the Stellar KLH protein. When the
protein is used with the immunotherapy, it can act as an immune stimulant,
carrier molecule, or therapeutic vaccine conjugation. The companies anticipate
the continued growth of their joint endeavor.
For more information, visit
http://stellarbiotechnologies.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment